ZygoFix received FDA 510(k) clearance to market its zLOCK Lumbar Facet Fixation System. This achievement was supported by compelling clinical evidence from the company’s ongoing European clinical study, marking a significant advancement in spinal fusion technology.
As an alternative to the traditional placement of screws and rods to create an artificial bridge, stabilizing the segment, the zLOCK system harnesses the spine’s innate bone structure to securely lock its connecting joints. Unlike traditional methods, the company’s implant adapts to the joint’s anatomy during insertion, offering stability with a minimally invasive procedure that can be performed in outpatient and ASC environments.
ZygoFix CEO Ofer Levy remarked, “Receiving FDA clearance for our zLOCK Lumbar Stabilization System is an exciting milestone, and I am very proud of the team that has worked hard to achieve this goal. The system has garnered significant interest in the US market and this clearance paves the way for us to introduce our transformative solution to the US market, fostering collaboration with leading surgeons and enhancing patient care.”
ZygoFix received FDA 510(k) clearance to market its zLOCK Lumbar Facet Fixation System. This achievement was supported by compelling clinical evidence from the company’s ongoing European clinical study, marking a significant advancement in spinal fusion technology.
As an alternative to the traditional placement of screws and rods to create an...
ZygoFix received FDA 510(k) clearance to market its zLOCK Lumbar Facet Fixation System. This achievement was supported by compelling clinical evidence from the company’s ongoing European clinical study, marking a significant advancement in spinal fusion technology.
As an alternative to the traditional placement of screws and rods to create an artificial bridge, stabilizing the segment, the zLOCK system harnesses the spine’s innate bone structure to securely lock its connecting joints. Unlike traditional methods, the company’s implant adapts to the joint’s anatomy during insertion, offering stability with a minimally invasive procedure that can be performed in outpatient and ASC environments.
ZygoFix CEO Ofer Levy remarked, “Receiving FDA clearance for our zLOCK Lumbar Stabilization System is an exciting milestone, and I am very proud of the team that has worked hard to achieve this goal. The system has garnered significant interest in the US market and this clearance paves the way for us to introduce our transformative solution to the US market, fostering collaboration with leading surgeons and enhancing patient care.”
Copy to clipboard 
